Daniel R Kuritzkes

List of Publications by Year
in descending order

106 papers	4,891 citations	101535 36 h-index	106340 65 g-index
112 all docs	112 docs citations	112 times ranked	7778 citing authors

#	Article	IF	Citations
1	Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort. Clinical Infectious Diseases, 2022, 75, e450-e458.	5.8	84
2	Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States. Open Forum Infectious Diseases, 2022, 9, .	0.9	2
3	Comparing effectiveness of firstâ€line antiretroviral therapy between periâ€urban and rural clinics in KwaZuluâ€Natal, South Africa. HIV Medicine, 2022, 23, 727-737.	2.2	2
4	Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. Clinical Infectious Diseases, 2022, 75, 1389-1396.	5.8	9
5	Prescribing Nirmatrelvirâ€“Ritonavir: How to Recognize and Manage Drugâ€“Drug Interactions. Annals of Internal Medicine, 2022, 175, 744-746.	3.9	35
6	Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatmentâ€limited individuals living with HIV. HIV Medicine, 2022, 23, 936-946.	2.2	12
7	Recommendations for the Management of Drugâ€“Drug Interactions Between the <scp>COVID</scp>â€19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Clinical Pharmacology and Therapeutics, 2022, 112, 1191-1200.	4.7	122
8	Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life. Clinical Infectious Diseases, 2021, 72, 388-393.	5.8	17
9	Mobile Health (mHealth) Viral Diagnostics Enabled with Adaptive Adversarial Learning. ACS Nano, 2021, 15, 665-673.	14.6	21
10	Viral Reservoir in Early-Treated Human Immunodeficiency Virus-Infected Children and Markers for Sustained Viral Suppression. Clinical Infectious Diseases, 2021, 73, e997-e1003.	5.8	11
11	Impact of pre-existing drug resistance on risk of virological failure in South Africa. Journal of Antimicrobial Chemotherapy, 2021, 76, 1558-1563.	3.0	13
12	Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. Open Forum Infectious Diseases, 2021, 8, ofab153.	0.9	20
13	Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. Aids, 2021, 35, 1333-1342.	2.2	90
14	COVID-19 and HIV infection co-pandemics and their impact: a review of the literature. AIDS Research and Therapy, 2021, 18, 28.	1.7	59
15	Adaptive adversarial neural networks for the analysis of lossy and domain-shifted datasets of medical images. Nature Biomedical Engineering, 2021, 5, 571-585.	22.5	15
16	Bamlanivimab for Prevention of COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 31.	7.4	13
17	Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, e234-e236.	2.1	13
18	Patterns of pretreatment drug resistance mutations of very early diagnosed and treated infants in Botswana. Aids, 2021, 35, 2413-2421.	2.2	6

#	Article	IF	Citations
19	38. Remdesivir Treatment in Patients Hospitalized with COVID-19: A Comparative Analysis of In-Hospital All-Cause Mortality. Open Forum Infectious Diseases, 2021, 8, S27-S28.	0.9	0
20	Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19. Antimicrobial Resistance and Infection Control, 2021, 10, 170.	4.1	2
21	Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to firstâ€line therapy in South Africa: a caseâ€“control cohort study. Journal of the International AIDS Society, 2021, 24, e25849.	3.0	5
22	Is France Once Again Looking for a Scapegoat?. Pathogens and Immunity, 2021, 6, 149-152.	3.1	1
23	Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. Clinical Infectious Diseases, 2020, 70, 1636-1642.	5.8	27
24	New Perspectives on the Virologic Consequences of M184V or I in Human Immunodeficiency Virus-1 Reverse Transcriptase. Journal of Infectious Diseases, 2020, 222, 1067-1069.	4.0	1
25	SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nature Communications, 2020, 11, 5493.	12.8	702
26	Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 235-241.	2.1	12
27	Plasma lipidome abnormalities in people with HIV initiating antiretroviral therapy. Translational Medicine Communications, 2020, 5, .	1.4	1
28	Determination of RNA structural diversity and its role in HIV-1 RNA splicing. Nature, 2020, 582, 438-442.	27.8	136
29	Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy. Journal of Infectious Diseases, 2020, 222, 1837-1842.	4.0	3
30	HIV diagnostic algorithm requires confirmatory testing for initial indeterminate or positive screens in the first week of life. Aids, 2020, 34, 1029-1035.	2.2	2
31	Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. Lancet HIV,the, 2020, 7, e193-e200.	4.7	41
32	Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366. AIDS Research and Human Retroviruses, 2020, 36, 268-282.	1.1	21
33	Recommendations for analytical antiretroviral treatment interruptions in HIV research trialsâ€"report of a consensus meeting. Lancet HIV,the, 2019, 6, e259-e268.	4.7	139
34	Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile. Science Translational Medicine, 2019, 11, .	12.4	74
35	Immunological and Neurometabolite Changes Associated With Switch From Efavirenz to an Integrase Inhibitor. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 585-593.	2.1	14
36	Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. Lancet HIV,the, 2019, 6, e116-e127.	4.7	84

#	Article	IF	Citations
37	The Sloth. Pathogens and Immunity, 2019, 4, 195.	3.1	0
38	What risk of death would people take to be cured of HIV and why? A survey of people living with HIV. Journal of Virus Eradication, 2019, 5, 109-115.	0.5	6
39	Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 125-135.	2.1	59
40	Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. Lancet HIV,the, 2018, 5, e146-e154.	4.7	61
41	Resistance to Dolutegravirâ€"A Chink in the Armor?. Journal of Infectious Diseases, 2018, 218, 673-675.	4.0	4
42	DNA engineered micromotors powered by metal nanoparticles for motion based cellphone diagnostics. Nature Communications, 2018, 9, 4282.	12.8	72
43	Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation. PLoS ONE, 2018, 13, e0197298.	2.5	6
44	NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. Blood Advances, 2018, 2, 1412-1416.	5.2	2
45	Targeted HIV testing at birth supported by low and predictable motherâ€toâ€child transmission risk in Botswana. Journal of the International AIDS Society, 2018, 21, e25111.	3.0	14
46	Motion-Based Immunological Detection of Zika Virus Using Pt-Nanomotors and a Cellphone. ACS Nano, 2018, 12, 5709-5718.	14.6	86
47	The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. Journal of Infectious Diseases, 2018, 218, 1954-1963.	4.0	130
48	HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. Journal of Clinical Investigation, 2018, 128, 4074-4085.	8.2	67
49	Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. PLoS Pathogens, 2018, 14, e1006856.	4.7	70
50	High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay. EBioMedicine, 2017, 20, 217-229.	6.1	50
51	Global HIV Antiretroviral Drug Resistance. Journal of Infectious Diseases, 2017, 216, S798-S800.	4.0	25
52	Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. Journal of Infectious Diseases, 2017, 216, 254-262.	4.0	41
53	Paper microchip with a graphene-modified silver nano-composite electrode for electrical sensing of microbial pathogens. Nanoscale, 2017, 9, 1852-1861.	5.6	58
54	Why cure, why now?. Journal of Medical Ethics, 2017, 43, 67-70.	1.8	17

#	Article	IF	Citations
55	Metagenomic Sequencing of an Echovirus 30 Genome From Cerebrospinal Fluid of a Patient With Aseptic Meningitis and Orchitis. Open Forum Infectious Diseases, 2017, 4, ofx138.	0.9	13
56	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Medicine, 2017, 14, e1002417.	8.4	186
57	Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS ONE, 2017, 12, e0181357.	2.5	31
58	Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration. PLoS Pathogens, 2017, 13, e1006478.	4.7	45
59	Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV. Pathogens and Immunity, 2017, 2, 376.	3.1	36
60	Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption. Pathogens and Immunity, 2017, 2, 431.	3.1	12
61	A Cure for HIV Infection: â€œNot in My Lifetimeâ€•or â€œJust Around the Cornerâ€?. Pathogens and Immunity, 2016, 1, 154.	3.1	35
62	Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants. EBioMedicine, 2016, 8, 237-247.	6.1	22
63	Evolution of coreceptor utilization to escape CCR5 antagonist therapy. Virology, 2016, 494, 198-214.	2.4	8
64	Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity. Antiviral Therapy, 2016, 22, 71-75.	1.0	11
65	HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-NaÃ¯ve Men and Women in the United States. AIDS and Behavior, 2016, 20, 2983-2995.	2.7	5
66	Elevated Levels of Microbial Translocation Markers and CCL2 Among Older HIV-1â€“Infected Men. Journal of Infectious Diseases, 2016, 213, 771-775.	4.0	17
67	Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV. PLoS Pathogens, 2016, 12, e1005535.	4.7	85
68	Printed Flexible Plastic Microchip for Viral Load Measurement through Quantitative Detection of Viruses in Plasma and Saliva. Scientific Reports, 2015, 5, 9919.	3.3	25
69	The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. Aids, 2015, 30, 1.	2.2	214
70	Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). Aids, 2015, 29, 2419-2426.	2.2	18
71	Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Î”32. Aids, 2015, 29, 867-876.	2.2	26
72	Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy. PLoS ONE, 2015, 10, e0139474.	2.5	25

#	Article	IF	Citations
73	Differential Levels of Soluble Inflammatory Markers by Human Immunodeficiency Virus Controller Status and Demographics. Open Forum Infectious Diseases, 2015, 2, ofu117.	0.9	54
74	Multitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 Td (States of America, 2015, 112, E4354-63.	7.1	56
75	Paper and Flexible Substrates as Materials for Biosensing Platforms to Detect Multiple Biotargets. Scientific Reports, 2015, 5, 8719.	3.3	148
76	Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy. PLoS ONE, 2014, 9, e90485.	2.5	27
77	Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study. Open Forum Infectious Diseases, 2014, 1, ofu018.	0.9	7
78	Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. Aids, 2014, 28, 181-186.	2.2	63
79	Micro-a-fluidics ELISA for Rapid CD4 Cell Count at the Point-of-Care. Scientific Reports, 2014, 4, 3796.	3.3	85
80	Nanostructured Optical Photonic Crystal Biosensor for HIV Viral Load Measurement. Scientific Reports, 2014, 4, 4116.	3.3	144
81	Lab-on-Chip: Acute On-Chip HIV Detection Through Label-Free Electrical Sensing of Viral Nano-Lysate (Small 15/2013). Small, 2013, 9, 2478-2478.	10.0	0
82	Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naive Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248. Journal of Infectious Diseases, 2013, 208, 884-891.	4.0	53
83	Long-Term Reduction in Peripheral Blood HIV Type 1 Reservoirs Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. Journal of Infectious Diseases, 2013, 207, 1694-1702.	4.0	250
84	Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-NaÃ¯ve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine. PLoS ONE, 2013, 8, e83514.	2.5	45
85	HAART for HIV-1 Infection: Zeroing In on When to Start. Archives of Internal Medicine, 2011, 171, 1569.	3.8	3
86	AIDS Clinical Trials Group 5197: A Placeboâ€Controlled Trial of Immunization of HIVâ€1â€“Infected Persons with a Replicationâ€Deficient Adenovirus Type 5 Vaccine Expressing the HIVâ€1 Core Protein. Journal of Infectious Diseases, 2010, 202, 705-716.	4.0	106
87	Development of a microfluidic system for measuring HIV-1 viral load. Proceedings of SPIE, 2010, 7666, 76661H.	0.8	7
88	Integrating microfluidics and lensless imaging for point-of-care testing. , 2009, , .		1
89	Preexisting Resistance to Nonnucleoside Reverseâ€Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenzâ€Based Regimen in Treatmentâ€Naive HIVâ€1â€“Infected Subjects. Journal of Infectious Diseases, 2008, 197, 867-870.	4.0	170
90	Domain 4 of ILY sensitizes antibody therapy on cancer and HIV through abrogating human CD59 function. FASEB Journal, 2008, 22, 522-522.	0.5	5

#	Article	IF	Citations
91	Plasma HIVâ€1 RNA Dynamics in Antiretroviralâ€Naive Subjects Receiving either Tripleâ€Nucleoside or Efavirenzâ€Containing Regimens: ACTG A5166s. Journal of Infectious Diseases, 2007, 195, 1169-1176.	4.0	40
92	HIV resistance: frequency, testing, mechanisms. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2007, 15, 150-4.	2.9	5
93	A Randomized Study of Antiviral Medication Switch at Lower-Versus Higher-Switch Thresholds: AIDS Clinical Trials Group Study A5115. Antiviral Therapy, 2007, 12, 531-541.	1.0	18
94	Intracellular Nucleoside Triphosphate Concentrations in HIV-Infected Patients on Dual Nucleoside Reverse Transcriptase Inhibitor Therapy. Antiviral Therapy, 2007, 12, 981-986.	1.0	24
95	Amdoxovir versus Placebo with Enfuvirtide plus Optimized Background Therapy for HIV-1-Infected Subjects Failing Current Therapy (Aactg A5118). Antiviral Therapy, 2006, 11, 619-623.	1.0	21
96	Design Issues in Initial HIV-Treatment Trials: Focus on Actg A5095. Antiviral Therapy, 2006, 11, 751-760.	1.0	13
97	Challenges for the Clinical Development of New Nucleoside Reverse Transcriptase Inhibitors for HIV Infection. Antiviral Therapy, 2005, 10, 13-28.	1.0	24
98	Quantification of Human Immunodeficiency Virus Type 1 by Reverse Transcriptaseâ€“Coupled Polymerase Chain Reaction. Journal of Infectious Diseases, 2004, 190, 2047-2054.	4.0	3
99	Ethical Conduct of Research in Resourceâ€Limited Settings. Journal of Infectious Diseases, 2004, 189, 764-765.	4.0	5
100	Preventing and Managing Antiretroviral Drug Resistance. AIDS Patient Care and STDs, 2004, 18, 259-273.	2.5	47
101	Extending antiretroviral therapy to resource-poor settings. Aids, 2004, 18, S45-S48.	2.2	10
102	Cardiovascular Risk Factors and Antiretroviral Therapy. New England Journal of Medicine, 2003, 348, 679-680.	27.0	23
103	Management of patients with virologic and metabolic failure. Aids Reader, 2003, 13, S17-22.	0.3	0
104	Effect of antiretroviral resistance on response in treatment-experienced patients. Aids Reader, 2003, 13, S5-11.	0.3	10
105	Early Intensification with Abacavir in Subjects at High Risk for Incomplete Viral Suppression. Antiviral Therapy, 2003, 8, 361-363.	1.0	1
106	Drug resistance. Navigating resistance pathways. Aids Reader, 2002, 12, 395-400, 407.	0.3	3